T1	Participants 428 531	Patients were assigned to a target dose of losartan 50 mg/day and captopril 50 mg t.i.d., as tolerated.
T2	Participants 100 427	(Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan) is the first major study to compare an angiotensin II Type 1 antagonist losartan (Cozaar trade mark, Merck) with an ACE inhibitor captonpril (Capoten trade mark, Elan) after myocardial infarction in patients with left ventricular dysfunction.
